7619-53-6 Usage
Description
Clomifene citrate, also known as cis-Clomiphene Citrate, is the cis isomer of Clomiphene (C587025). It is a selective estrogen receptor modulator (SERM) with antiestrogenic properties and is recognized as a more potent inhibitor of luteinizing hormone (LH) secretion than its trans isomer. Clomifene citrate is widely used in the medical field for various applications due to its unique characteristics.
Uses
Used in Reproductive Medicine:
Clomifene citrate is used as a fertility drug for the treatment of infertility in women. It works by stimulating the release of hormones necessary for ovulation, thereby increasing the chances of conception.
Used in Oncology:
Clomifene citrate is used as an anticancer agent, particularly in the treatment of estrogen receptor-positive breast cancer. Its antiestrogenic properties help in blocking the effects of estrogen, which can promote the growth of cancer cells.
Used in Endocrinology:
Clomifene citrate is used as a diagnostic tool for the evaluation of pituitary-gonadal function. It can help in determining the cause of infertility by assessing the patient's response to the drug.
Used in Drug Delivery Systems:
Clomifene citrate can be incorporated into novel drug delivery systems to enhance its bioavailability, targeting, and therapeutic outcomes. These systems may include nanoparticles, liposomes, or other advanced drug delivery technologies to improve the drug's efficacy and reduce potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 7619-53-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,6,1 and 9 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 7619-53:
(6*7)+(5*6)+(4*1)+(3*9)+(2*5)+(1*3)=116
116 % 10 = 6
So 7619-53-6 is a valid CAS Registry Number.
7619-53-6Relevant articles and documents
Stereoselective Nickel(II)-Catalyzed Addition of Aryl Grignards to Diphenylacetylene in the Synthesis of Zuclomiphene
Karadeolian, Avedis,Emmett, Michael,Souza, Fabio,Chung, Andrew,Blazecka, Peter,Le Sueur, Richard,Patel, Dineshkumar,Zhao, Yajun,Rey, Allan,Green, Stuart
, p. 1124 - 1129 (2022/03/16)
Stereoselective synthesis of zuclomiphene was developed using nickel-catalyzed addition of 4-fluorophenylmagnesium bromide to 1,2-diphenylacetylene, followed by quenching with a chlorinating reagent. Since the aryl fluoride addition and chlorination reactions occur consecutively in one pot, the cis orientation of the two phenyl groups of 1,2-diphenylacetylene is conserved, leading to the highly selective synthesis of zuclomiphene. The use of the Grignard reagent resulted in the presence of bromide ions in the reaction mixture, which led to the formation of the bromo-analog of zuclomiphene. Alternative routes were then explored to overcome this issue to yield high-purity zuclomiphene.
Crystalline Forms of Zuclomiphene Citrate
-
Paragraph 0068-0073, (2021/07/24)
The present invention provides novel crystalline forms of zuclomiphene citrate. Specific crystalline forms provided by the present invention include zuclomiphene citrate Forms APO-I, APO-II, APO-III, and APO-IV. Also provided are pharmaceutical compositions including the zuclomiphene citrate crystalline forms, processes for the preparation thereof and the use of these forms in the treatment of a disorder selected from the group including osteoporosis, bone fractures, loss of bone mineral density (BMD) and hot flashes in a subject suffering therefrom.